Physician profile
Daniel Parnassa
NPI 1528049483
$12,400.93
in general payments reported to CMS, 2019-2025
33 companies · $1,429 in 2025
The $1,429 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,896 · 2020: $1,495 · 2021: $1,547 · 2022: $2,297 · 2023: $2,231 · 2024: $1,505 · 2025: $1,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,165.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,127.67 | 2019-2024 | Xarelto |
| Amgen INC. | $1,001.08 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $863.75 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $781.16 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $779.98 | 2019-2025 | Farxiga, Wainua |
| Abbott Laboratories | $763.74 | 2019-2024 | Aveir, Mitraclip |
| Alnylam Pharmaceuticals INC. | $744.75 | 2022-2025 | Onpattro, Amvuttra |
| Novartis Pharmaceuticals Corporation | $668.04 | 2019-2025 | |
| Pfizer INC. | $629.42 | 2019-2025 | |
| Philips North America LLC | $560.91 | 2020-2025 | (Ck7) Extended Holter, Extended Holter, Ecc Solutions |
| Sanofi-Aventis U.S. LLC | $543.79 | 2019-2023 | |
| Boston Scientific Corporation | $514.59 | 2019-2025 | Watchman Flx, Bodyguardian, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $471.36 | 2019-2023 | Jardiance |
| Esperion Therapeutics, INC. | $437.55 | 2020-2025 | Nexletol |
| Astellas Pharma US INC | $389.76 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $329.92 | 2019-2021 | |
| Biotronik INC. | $311.39 | 2020-2023 | Amvia Edge, Edora 8 Dr-T, Rivacor 7 Dr-T |
| Bayer Healthcare Pharmaceuticals INC. | $268.85 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $214.65 | 2022-2025 | Lifevest |
| Cvrx, INC. | $201.67 | 2023-2025 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $128.81 | 2019-2025 | Opsumit |
| Regeneron Healthcare Solutions, INC. | $125.95 | 2019 | |
| Genzyme Corporation | $125.00 | 2019 | |
| Lilly USA, LLC | $92.72 | 2019 | |
| Novo Nordisk INC | $65.73 | 2019 | |
| Heartflow, INC. | $59.41 | 2025 | |
| Kestra Medical Technology Services, INC. | $57.52 | 2023-2025 | Assure Wcd |
| Braemar Manufacturing, LLC | $49.28 | 2019 | |
| Medtronic Vascular, INC. | $32.41 | 2020 | |
| Inspire Medical Systems, INC. | $23.30 | 2023 | Inspire |
| Medicure Pharma INC. | $13.36 | 2025 | Zypitamag |
| Ethicon US, LLC | $11.78 | 2019 | |
| Coala Life INC | $11.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Parnassa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.